Moderna said Monday that its experimental COVID-19 vaccine was nearly 95 percent effective at preventing infections, in the first glimpse of data from its late-stage clinical trial. The Cambridge biotech said it hopes to seek emergency use for at least some people “in the coming weeks.”
The first interim review of data in the study of more than 30,000 volunteers indicated that the two-dose vaccine showed about the same remarkable effectiveness as a rival one being tested by the pharmaceutical giant Pfizer. That company reported a week ago that two doses of its vaccine appeared to be more than 90 percent effective.
We have lots of e-mail newsletters on a variety of topics, including news, politics, business, sports, lifestyle, and more. They're free, and it's easy to subscribe. Here's a complete list.
You received this message because you signed up for Breaking News Alerts.
